IDEAL_ANSWER:
- Immune checkpoint blocking monoclonal antibodies are heralded as a promising therapeutic approach in clinical oncology. These mAbs do not directly attack the malignant cells as most anticancer mAbs; rather, they enhance the anti-tumor response of the immune system by targeting immune regulatory pathways.

EXACT_ANSWER:
- monoclonal antibody drugs that regulate the immune response to cancer